#Canada #Toronto #Semaglutide #Apotex Health #Revlimid

Apotex Reports Strong Q1 2027 Performance with 11% Revenue Growth

Apotex Health Corp. has officially revealed its financial and operational outcomes for the first quarter of fiscal year 2027, ending June 30, 2026. This marks a corner for the company as it continues on its journey as a public entity, showcasing its resilience in the competitive pharmaceutical landscape. The report indicates an impressive 11% growth in revenue within Canada, contributing to a total revenue of $848 million CAD. This continues Apotex's commitment to accessibility and the delivery of innovative health solutions.

Revenue Highlights

The results highlight a resilient performance despite the absence of contributions from the generic Revlimid product, which significantly impacted financial comparisons from previous years. Excluding the effects of this product, Apotex noted a 2% increase in revenue, driven mainly by the successful launches of new therapies. The launch of semaglutide, a first-to-market product in Canada aimed at weight management, is one of the highlights contributing to this revenue boost.

Performance by Region

In their financial breakdown, the company reported that:

• - Canada: Revenue increased by $43 million CAD, bringing the total to $413 million CAD for the quarter.
• - USA: Excluding Revlimid's contribution, revenue decreased by about 9% due to increased competition from generic products and a temporary pause in ophthalmic product sales.
• - International: A minor increase of 8% was observed, notably attributed to sales growth in Latin America, showing focused efforts in international territories.

Comparison with Previous Financial Performance

Despite the progress reported, comparisons year-over-year reflect challenges from the prior year's high revenue contributions from Revlimid. The reported revenue saw a downturn of approximately 26%, but this facilitated showcasing their core business performance metric, which indicates stability and growth in established generics excluding VLLP contributions.

Business Lines Overview

A detailed analysis of performance across various business lines showed that:

• - Conventional Generics Excluding VLLP saw impressive growth, with revenue up 16% compared to the same quarter last year, totaling $431 million CAD.
• - Conversely, Specialty Generics reported a decline of 19%, citing competitive pressures due to market dynamics of expiring patents.
• - The Brands & Biosimilars segment grew about 8%, offering a more diversified approach to support the company's extensive portfolio.

EBITDA and Margins

Apotex also maintained a solid Adjusted EBITDA of $259 million CAD with a margin of 31%. Interventions aimed at cost management and operational efficiencies have contributed positively amidst fluctuating sales dynamics.

CEO Jeff Watson expressed optimism, stating that the quarter indicates the effective execution of the Journey of Health strategy, focusing on broadening access to medicines and launching innovative products that are critical in today’s healthcare sector.

CFO Brian McClelland, detailing their financial strengthening efforts, remarked on the improved leverage and reduced debt, supported by a recently upsized IPO. This stability enhances their capability for capital allocation and strategic growth initiatives.

Forward-Looking Guidance

Looking ahead, Apotex aims for upper mid-single-digit revenue growth for the fiscal year 2027 reiterating its targets of significant launches in both the Canadian and U.S. markets. The company remains focused on achieving a sustained Adjusted EBITDA margin of approximately 30%, standardizing efficiency and productivity as core operational goals.

In summary, Apotex Health Corp. continues to position itself as a leader in generics while navigating market challenges and leveraging growth opportunities through innovation and strategic partnerships. The recently announced plans and financial discipline bode well for the future, setting a promising roadmap for sustainable growth in health services.